PriceTargets.com logo

Shield Therapeutics - STX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 15
  • Forecasted Upside: 35.96%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 11.03 As of 12/5/2025 06:42 AM ET
▼ -0.267 (-2.36%)

This chart shows the closing price for STX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Shield Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STX

Analyst Price Target is GBX 15
▲ +35.96% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Shield Therapeutics in the last 3 months. The average price target is GBX 15, with a high forecast of GBX 15 and a low forecast of GBX 15. The average price target represents a 35.96% upside from the last price of GBX 11.03.

This chart shows the closing price for STX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Shield Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/7/2025Peel HuntReiterated RatingBuyGBX 15
10/1/2025Peel HuntReiterated RatingBuyGBX 15
9/15/2025Peel HuntReiterated RatingBuyGBX 15
2/9/2023Peel HuntReiterated RatingBuy
6/24/2021Peel HuntReiterated RatingBuy
6/24/2021Peel HuntReiterated RatingBuy
5/18/2021Peel HuntReiterated RatingBuy
5/18/2021Peel HuntReiterated RatingBuy
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Shield Therapeutics logo
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc. (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. Feraccru® is commercialized in the UK and European Union by Norgine B.V. (Norgine), which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer®/ Feraccru® in China, Hong Kong, Macau and Taiwan; with Korea Pharma Co., Ltd. for the Republic of Korea (Korea Pharma); and with KYE Pharmaceuticals Inc. for Canada. Accrufer®/Feraccru® has patent coverage until the mid-2030s. Accrufer®/Feraccru® are registered trademarks of Shield Therapeutics.
Read More

Today's Range

Now: GBX 11.03
Low: 10.95
High: 11.50

50 Day Range

MA: GBX 7.72
Low: 6.44
High: 11.80

52 Week Range

Now: GBX 11.03
Low: 2.10
High: 12.50

Volume

2,025,836 shs

Average Volume

2,897,786 shs

Market Capitalization

£117.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Shield Therapeutics?

The following sell-side analysts have issued reports on Shield Therapeutics in the last twelve months: Peel Hunt.
View the latest analyst ratings for STX.

What is the current price target for Shield Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Shield Therapeutics in the last year. Their average twelve-month price target is GBX 15, suggesting a possible upside of 30.4%. Peel Hunt has the highest price target set, predicting STX will reach GBX 15 in the next twelve months. Peel Hunt has the lowest price target set, forecasting a price of GBX 15 for Shield Therapeutics in the next year.
View the latest price targets for STX.

What is the current consensus analyst rating for Shield Therapeutics?

Shield Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe STX will outperform the market and that investors should add to their positions of Shield Therapeutics.
View the latest ratings for STX.

What other companies compete with Shield Therapeutics?

Other companies that are similar to Shield Therapeutics include El Oro, TAO Alpha, Apc Technology Group, DG Innovate and Ideagen. Learn More about companies similar to Shield Therapeutics.

How do I contact Shield Therapeutics' investor relations team?

Shield Therapeutics' physical mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company's listed phone number is +44-191-5118500. The official website for Shield Therapeutics is www.shieldtherapeutics.com. Learn More about contacing Shield Therapeutics investor relations.